Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,219,953
  • Shares Outstanding, K 98,969
  • Annual Sales, $ 248,070 K
  • Annual Income, $ -63,560 K
  • 60-Month Beta 2.38
  • Price/Sales 28.25
  • Price/Cash Flow N/A
  • Price/Book 48.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.00
  • Number of Estimates 4
  • High Estimate 0.04
  • Low Estimate -0.05
  • Prior Year -0.17
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.10 +18.61%
on 01/31/20
98.84 -3.88%
on 01/22/20
+2.43 (+2.62%)
since 01/17/20
3-Month
72.90 +30.33%
on 01/06/20
98.84 -3.88%
on 01/22/20
+9.26 (+10.80%)
since 11/18/19
52-Week
41.51 +128.88%
on 04/17/19
98.84 -3.88%
on 01/22/20
+41.82 (+78.62%)
since 02/15/19

Most Recent Stories

More News
NASDAQ Reaches New Closing High as Rebound Continues

NASDAQ Reaches New Closing High as Rebound Continues

LYV : 74.13 (+0.15%)
NVCR : 95.01 (+1.99%)
VRTX : 245.93 (+0.87%)
GDS : 60.54 (+0.28%)
ETSY : 53.32 (+0.30%)
AYX : 156.64 (-0.86%)
HTHT : 35.50 (-3.82%)
MGM : 32.02 (+1.59%)
NEM : 45.58 (+3.43%)
WYNN : 133.46 (+1.00%)
SIMO : 46.72 (+1.24%)
RXN : 35.11 (-0.51%)
GOOGL : 1,519.44 (+0.05%)
NVDA : 296.57 (+2.34%)
SQQQ : 16.45 (-0.24%)
SPXU : 17.45 (+0.75%)
BRY : 7.28 (-0.07%)
Expand Your Portfolio with this First Profit Stock Screener

Expand Your Portfolio with this First Profit Stock Screener

SPWR : 9.21 (+10.43%)
NVCR : 95.01 (+1.99%)
NEP : 61.23 (+1.95%)
EVER : 42.70 (+4.10%)
CRSP : 55.69 (-0.20%)
Relief Rally Snaps the Dow's 5-Day Losing Skid

Relief Rally Snaps the Dow's 5-Day Losing Skid

CREE : 47.07 (-2.77%)
RLI : 94.71 (-1.31%)
SCS : 18.94 (-0.53%)
SAM : 425.98 (+4.17%)
WYNN : 133.46 (+1.00%)
LNG : 55.23 (+0.45%)
TXN : 131.24 (-0.73%)
WY : 30.12 (-1.76%)
TWTR : 38.06 (+3.12%)
AMZN : 2,155.67 (+0.97%)
BZUN : 32.39 (-1.49%)
GDS : 60.54 (+0.28%)
IRBT : 51.51 (-5.31%)
LYV : 74.13 (+0.15%)
NVCR : 95.01 (+1.99%)
SPR : 66.60 (-1.93%)
CELH : 6.20 (+1.97%)
AMSC : 7.72 (-2.03%)
CLS : 7.87 (-2.24%)
Novocure Announces National Reimbursement in Israel for Optune(R) in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients...

NVCR : 95.01 (+1.99%)
NVE Corporation Schedules Conference Call on Third-Quarter Results

NVE Corporation (Nasdaq: NVEC) announced that it plans to release its financial results for the quarter and nine months ended December 31, 2019 on Wednesday, January 22, 2020 after the close of the Nasdaq...

NVCR : 95.01 (+1.99%)
NVEC : 72.10 (-1.25%)
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update

--Novocure to present at the 38th Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST on Monday, Jan. 13, 2020

JPM : 135.64 (-1.32%)
NVCR : 95.01 (+1.99%)
Cardiva Medical Appoints Jeri Hilleman to the Company's Board of Directors

Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl ("Jeri") Hilleman to the company's Board of Directors.

JPM : 135.64 (-1.32%)
NVCR : 95.01 (+1.99%)
NERV : 9.08 (+4.13%)
SIBN : 20.59 (-0.10%)
XENT : 27.50 (-5.11%)
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology...

NVCR : 95.01 (+1.99%)
ZLAB : 61.10 (+0.94%)
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure's Executive Chairman, will speak on...

JPM : 135.64 (-1.32%)
NVCR : 95.01 (+1.99%)
SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its...

SIBN : 20.59 (-0.10%)
NVCR : 95.01 (+1.99%)
NERV : 9.08 (+4.13%)
XENT : 27.50 (-5.11%)
AMRS : 3.41 (-9.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 97.13
1st Resistance Point 96.07
Last Price 95.01
1st Support Level 93.07
2nd Support Level 91.13

See More

52-Week High 98.84
Last Price 95.01
Fibonacci 61.8% 76.94
Fibonacci 50% 70.18
Fibonacci 38.2% 63.41
52-Week Low 41.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar